Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567016 | 0.81 | HPGD (1.00) | HPGDKMT2APOLBALDH1A1KDM4E | |
| SCHEMBL6077865 | 0.80 | HPGD (0.97) | HPGDKMT2APOLBALDH1A1KDM4E | |
| SCHEMBL15528611 | 0.80 | KDM4E (0.60) | HPGDKMT2APOLBALDH1A1LMNA | |
| SCHEMBL15528367 | 0.78 | KDM4E (0.58) | HPGDKMT2APOLBRXFP1ALDH1A1 | |
| SCHEMBL15528271 | 0.78 | ALDH1A1 (0.54) | HPGDRXFP1ALDH1A1LMNAKDM4E | |
| SCHEMBL15530570 | 0.78 | RXFP1 (0.72) | HPGDRXFP1ALDH1A1LMNAKDM4E | |
| SCHEMBL15529987 | 0.76 | RXFP1 (0.60) | HPGDPOLBRXFP1ALDH1A1LMNA | |
| SCHEMBL15528295 | 0.74 | RXFP1 (0.75) | HPGDRXFP1ALDH1A1LMNAKDM4E | |
| SCHEMBL14855799 | 0.74 | ALDH1A1 (0.70) | HPGDRXFP1ALDH1A1LMNAKDM4E | |
| SCHEMBL15531139 | 0.73 | RXFP1 (0.71) | HPGDRXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844345-B1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | US HEALTH (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10125112-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| EP-2844345-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | The United States of America, as Represented by The Secretary, Department of Health and Human Services (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013165606-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | HPGD 1000/4885KMT2A 4449/4885POLB 4687/4885 |
| US-10125112-B2 | Modulators of the relaxin receptor 1 | RXFP1, RXFP2, RXFP3 | HPGD 1000/4885KMT2A 4449/4885POLB 4687/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | HPGD 1000/4885KMT2A 4449/4885POLB 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.